Grifols S.A. ADR (GRFS)

$9.46 -0.09 (-0.94%)
Market Cap 6.57B
Revenue (ttm) 7.80B
Net Income (ttm) 169.80M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 9.32
Profit Margin 2.18%
Debt to Equity Ratio 1.27
Volume 383,900
Avg Vol 540,054
Day's Range N/A - N/A
Shares Out 687.56M
Stochastic %K 38%
Beta 0.69
Analysts Sell
Price Target $12.15

Company Profile

Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma, and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factor VIII/von Willebrand factor and factor IX, clo...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 34 935 712 200
Fax: 34 938 008 000
Address:
Avinguda de la Generalitat 152-158, Parque Empresarial Can Sant Joan Sant Cugat del Valles, Barcelona, Spain
NVDAMillionaire
NVDAMillionaire Oct. 3 at 2:31 PM
$GRFS Brilliant piece that captures GRFS's situation perfectly. So if you want to update your understanding of GRFS or get to know GRFS better, this is essential reading. https://beyondspx.com/quote/GRFS/analysis/grifols-nasdaq-grfs-plasma-powerhouse-unleashes-growth-and-deleveraging-momentum
0 · Reply
topstockalerts
topstockalerts Sep. 26 at 5:04 PM
U.S. plans for new pharmaceutical tariffs are seen as negative due to uncertainty but could be an “opportunity” for Grifols, which is fully vertically integrated in the U.S. Banco Sabadell analysts noted the 100% tariff announcement on foreign branded or patented drugs unless companies establish U.S. manufacturing. While the news creates noise, details remain unclear, especially for firms already present in the U.S. Sanofi has announced $ 20B investment in the U.S. through 2030. Grifols is expected to face no negative impact, with ~70% of plasma collection and ~65% of production capacity in the U.S. Analysts see tariffs as a potential advantage for Grifols, the only fully vertically integrated hemoderivatives company in the country. Almirall’s impact would be minimal (~4.5% of sales in the U.S.), and Rovi is unlikely to be affected due to no direct distribution or branded products in the U.S. $GRFS $SNY $ALM $ROVI
0 · Reply
TradeJizzer
TradeJizzer Aug. 14 at 2:18 AM
$GRFS Breaking on X: Grifols just got busted for taking donated blood and selling it. This may gap down in the am.
0 · Reply
Doozio
Doozio Aug. 2 at 6:15 PM
$GRFS dips appears a 🎁 during 🐒🍌🧠⏰♾️
0 · Reply
RunnerSignals
RunnerSignals Jul. 29 at 9:07 PM
$CELC $GRFS $HIMS $ECX $ODP Comeback Kings shook off the midday dips and closed strong
0 · Reply
DonCorleone77
DonCorleone77 Jul. 29 at 5:17 PM
$GRFS Grifols reports Q2 revenue EUR 1.89B vs. EUR 1.79B last quarter -- Q2 profit EUR 191M vs. EUR 115M last quarter. -- Reinstates dividend of EUR 0.15 per share -- Affirms 2025 guidance from capital markets day
0 · Reply
BeefStewart
BeefStewart Jul. 17 at 8:14 PM
$CERS Looks like some plasma-related stocks are just lagging $ADMA $GRFS ....
0 · Reply
Messerschmittbf109
Messerschmittbf109 Jun. 24 at 9:07 PM
$GRFS Grifols paid a higher price to buy blood plasma from an entity linked to its controlling family than from third-party suppliers, according to a regulator’s findings submitted in a court case ….
0 · Reply
Messerschmittbf109
Messerschmittbf109 Jun. 24 at 6:59 AM
$GRFS Grifols pagó hasta un 39% más para comprar plasma a Scranton Según las conclusiones de un regulador presentadas en un caso judicial, la farmacéutica española también acordó pagar a Scranton un margen fijo del 16,5% sobre los costes Bad news
0 · Reply
Messerschmittbf109
Messerschmittbf109 Jun. 23 at 8:15 PM
$GRFS bad news ? Weird day
0 · Reply
Latest News on GRFS
Spanish court summons Gotham City founder in Grifols share price probe

Oct 9, 2025, 8:15 AM EDT - 16 days ago

Spanish court summons Gotham City founder in Grifols share price probe

My Top 5 Biotech Stocks Big Pharma Could Buy Next

Oct 6, 2025, 1:29 PM EDT - 19 days ago

My Top 5 Biotech Stocks Big Pharma Could Buy Next

ABBV ALVO AMGN ARKG AZN BIIB BMY

Grifols: Significant Upside Likely Materializing

Oct 2, 2025, 9:23 PM EDT - 22 days ago

Grifols: Significant Upside Likely Materializing

XL-protein grants worldwide license to Grifols to develop a biopharmaceutical using PASylation® technology

Jun 10, 2025, 5:00 AM EDT - 4 months ago

XL-protein grants worldwide license to Grifols to develop a biopharmaceutical using PASylation® technology

Mason Capital Management to Support Grifols Recommended Director Slate at Upcoming Ordinary General Meeting

May 30, 2025, 4:05 PM EDT - 5 months ago

Mason Capital Management to Support Grifols Recommended Director Slate at Upcoming Ordinary General Meeting

US court finds enough evidence to proceed with Grifols lawsuit against Gotham City

May 30, 2025, 3:15 AM EDT - 5 months ago

US court finds enough evidence to proceed with Grifols lawsuit against Gotham City

Grifols: If This Works Out, It Has Massive Upside

May 22, 2025, 12:09 PM EDT - 5 months ago

Grifols: If This Works Out, It Has Massive Upside

Grifols, S.A. (GRFS) Q1 2025 Earnings Conference Call Transcript

May 12, 2025, 4:51 PM EDT - 5 months ago

Grifols, S.A. (GRFS) Q1 2025 Earnings Conference Call Transcript

Grifols says on course to meet 2025 outlook as net profit triples

May 12, 2025, 2:47 PM EDT - 5 months ago

Grifols says on course to meet 2025 outlook as net profit triples

IBL International collaborates with Grifols on advanced biomarker panels

Apr 8, 2025, 9:29 AM EDT - 7 months ago

IBL International collaborates with Grifols on advanced biomarker panels

Brookfield resumes Grifols takeover talks, El Confidencial reports

Apr 2, 2025, 3:03 AM EDT - 7 months ago

Brookfield resumes Grifols takeover talks, El Confidencial reports

Grifols: Looking At The Longer-Term 2025-2027 Upside After No Sale

Feb 27, 2025, 12:58 PM EST - 8 months ago

Grifols: Looking At The Longer-Term 2025-2027 Upside After No Sale

Grifols expects to boost revenue and free cash flow, shares soar

Feb 27, 2025, 11:23 AM EST - 8 months ago

Grifols expects to boost revenue and free cash flow, shares soar

Grifols' sales rise over 10% in 2024, above target

Feb 26, 2025, 12:18 PM EST - 8 months ago

Grifols' sales rise over 10% in 2024, above target

Blood Plasma Derivatives Market Insights and Forecast 2025-2030 - Grifols, SK Plasma, and Fusion Health Care Lead the Competition

Feb 6, 2025, 6:07 AM EST - 9 months ago

Blood Plasma Derivatives Market Insights and Forecast 2025-2030 - Grifols, SK Plasma, and Fusion Health Care Lead the Competition

Grifols Pioneers High-Tech Analysis of Plasma Bank to Detect Early Signs of Parkinson's Disease

Jan 14, 2025, 6:00 AM EST - 10 months ago

Grifols Pioneers High-Tech Analysis of Plasma Bank to Detect Early Signs of Parkinson's Disease

Mason Capital complains about Grifols' transparency to Spanish regulator

Jan 13, 2025, 10:55 AM EST - 10 months ago

Mason Capital complains about Grifols' transparency to Spanish regulator

Mason Capital Management Sends Letter to Spanish National Securities Market Commission Regarding Lack of Transparency by Grifols

Jan 13, 2025, 10:00 AM EST - 10 months ago

Mason Capital Management Sends Letter to Spanish National Securities Market Commission Regarding Lack of Transparency by Grifols

Flat Footed Calls for Prompt Governance Overhaul at Grifols

Dec 10, 2024, 12:23 PM EST - 11 months ago

Flat Footed Calls for Prompt Governance Overhaul at Grifols

Spain's market regulator sees signs of manipulation in Grifols-Gotham dispute

Dec 5, 2024, 7:05 AM EST - 11 months ago

Spain's market regulator sees signs of manipulation in Grifols-Gotham dispute

Mason Capital Management Requests Immediate Disclosure of Important Information Regarding Conflicted Grifols Director Tomas Daga

Dec 4, 2024, 2:30 AM EST - 11 months ago

Mason Capital Management Requests Immediate Disclosure of Important Information Regarding Conflicted Grifols Director Tomas Daga

Statement From Araoz y Rueda on Behalf of Certain Institutional Investors in Grifols

Dec 4, 2024, 2:00 AM EST - 11 months ago

Statement From Araoz y Rueda on Behalf of Certain Institutional Investors in Grifols

Grifols: More Attractive Than In A Very Long Time

Nov 29, 2024, 12:30 PM EST - 11 months ago

Grifols: More Attractive Than In A Very Long Time

Why Is Spanish Healthcare Grifols Stock Trading Lower On Friday?

Nov 29, 2024, 9:29 AM EST - 11 months ago

Why Is Spanish Healthcare Grifols Stock Trading Lower On Friday?

Grifols shares tumble after report on Brookfield abandoning takeover plan

Nov 27, 2024, 3:25 AM EST - 11 months ago

Grifols shares tumble after report on Brookfield abandoning takeover plan

Grifols: Brookfields potential $6.8 bln offer undervalues the firm

Nov 19, 2024, 8:25 AM EST - 1 year ago

Grifols: Brookfields potential $6.8 bln offer undervalues the firm

Spanish court opens investigation into Gotham City's attack on Grifols

Nov 19, 2024, 5:54 AM EST - 1 year ago

Spanish court opens investigation into Gotham City's attack on Grifols

Mason Capital Reiterates Corporate Governance Shortcomings and Mismanagement of Grifols Under Current Board of Directors

Nov 19, 2024, 2:30 AM EST - 1 year ago

Mason Capital Reiterates Corporate Governance Shortcomings and Mismanagement of Grifols Under Current Board of Directors

Brookfield mulls $7.4 bln bid for Spain's Grifols, El Confidencial says

Nov 18, 2024, 2:58 AM EST - 1 year ago

Brookfield mulls $7.4 bln bid for Spain's Grifols, El Confidencial says

Mason Capital Management Highlights Corporate Governance Failures and Significant Shareholder Value Destruction Under Grifols Board of Directors

Nov 8, 2024, 3:54 PM EST - 1 year ago

Mason Capital Management Highlights Corporate Governance Failures and Significant Shareholder Value Destruction Under Grifols Board of Directors

Grifols on track to meet 2024 targets despite third-quarter profit drop

Nov 7, 2024, 11:58 AM EST - 1 year ago

Grifols on track to meet 2024 targets despite third-quarter profit drop

Grifols: Here Is Why It's Still A 'Buy' Even If Price Goes Down

Oct 3, 2024, 5:20 PM EDT - 1 year ago

Grifols: Here Is Why It's Still A 'Buy' Even If Price Goes Down

Grifols plans to invest $402 million in new industrial centre, El Economista says

Sep 30, 2024, 3:12 AM EDT - 1 year ago

Grifols plans to invest $402 million in new industrial centre, El Economista says

Significant Shareholders Exercise Right to Grifols Board Seat

Sep 19, 2024, 3:23 PM EDT - 1 year ago

Significant Shareholders Exercise Right to Grifols Board Seat

Grifols Egypt Collaborates with Orange Business to Deliver New Data Center and Communications Infrastructure, Supporting Advanced Medical Processes

Sep 11, 2024, 4:00 AM EDT - 1 year ago

Grifols Egypt Collaborates with Orange Business to Deliver New Data Center and Communications Infrastructure, Supporting Advanced Medical Processes

The Schall Law Firm Is Looking Into Grifols SA For Possible Securities Related Improprieties And Stockholders Are Invited To Reach Out

Sep 6, 2024, 11:00 AM EDT - 1 year ago

The Schall Law Firm Is Looking Into Grifols SA For Possible Securities Related Improprieties And Stockholders Are Invited To Reach Out

Grifols S.A. May Have Committed Fraud And Investors Are Urged To Contact The Schall Law Firm About An Inquiry

Sep 5, 2024, 11:00 AM EDT - 1 year ago

Grifols S.A. May Have Committed Fraud And Investors Are Urged To Contact The Schall Law Firm About An Inquiry

The Schall Law Firm Is Looking Into Grifols SA For Possibly Violating Securities Laws And Stakeholders Are Invited To Partake In The Investigation

Sep 4, 2024, 11:00 AM EDT - 1 year ago

The Schall Law Firm Is Looking Into Grifols SA For Possibly Violating Securities Laws And Stakeholders Are Invited To Partake In The Investigation

Grifols SA May Have Committed Securities Fraud And Investors With Losses Should Join The Schall Law Firm's Inquiry

Sep 3, 2024, 11:00 AM EDT - 1 year ago

Grifols SA May Have Committed Securities Fraud And Investors With Losses Should Join The Schall Law Firm's Inquiry

Grifols SA Is Being Looked Into For Securities Fraud And Investors Should Reach Out To The Schall Law Firm About The Inquiry

Sep 1, 2024, 11:00 AM EDT - 1 year ago

Grifols SA Is Being Looked Into For Securities Fraud And Investors Should Reach Out To The Schall Law Firm About The Inquiry

Grifols SA May Have Committed Securities Fraud And Stakeholders Are Invited To Join The Schall Law Firm's Inquiry

Aug 30, 2024, 11:00 AM EDT - 1 year ago

Grifols SA May Have Committed Securities Fraud And Stakeholders Are Invited To Join The Schall Law Firm's Inquiry

The Schall Law Firm Is Looking Into Whether Grifols S.A. Violated Securities Regulations And Investors Are Urged To Reach Out

Aug 29, 2024, 11:00 AM EDT - 1 year ago

The Schall Law Firm Is Looking Into Whether Grifols S.A. Violated Securities Regulations And Investors Are Urged To Reach Out

An Investigation Has Been Launched Into Grifols SA For Securities Fraud And The Schall Law Firm Invites Shareholder Participation

Aug 28, 2024, 11:00 AM EDT - 1 year ago

An Investigation Has Been Launched Into Grifols SA For Securities Fraud And The Schall Law Firm Invites Shareholder Participation

Grifols SA Is Being Inquired Into For Securities Violations And Investors Are Encouraged To Contact The Schall Law Firm

Aug 27, 2024, 11:00 AM EDT - 1 year ago

Grifols SA Is Being Inquired Into For Securities Violations And Investors Are Encouraged To Contact The Schall Law Firm

The Schall Law Firm Urges Shareholders To Join An Investigation Into Grifols SA's Possible Securities Fraud

Aug 26, 2024, 11:00 AM EDT - 1 year ago

The Schall Law Firm Urges Shareholders To Join An Investigation Into Grifols SA's Possible Securities Fraud

An Inquiry Has Been Launched Into Grifols SA For Securities Law Infractions And The Schall Law Firm Is Seeking Investor Participation

Aug 25, 2024, 11:00 AM EDT - 1 year ago

An Inquiry Has Been Launched Into Grifols SA For Securities Law Infractions And The Schall Law Firm Is Seeking Investor Participation

Grifols SA Is Being Investigated By The Schall Law Firm For Securities Fraud And Stakeholders Are Urged To Take Part

Aug 24, 2024, 11:00 AM EDT - 1 year ago

Grifols SA Is Being Investigated By The Schall Law Firm For Securities Fraud And Stakeholders Are Urged To Take Part

The Schall Law Firm Has Launched An Inquiry Into Grifols SA For Potential Securities Violations And Stockholders Are Invited To Assist

Aug 23, 2024, 11:00 AM EDT - 1 year ago

The Schall Law Firm Has Launched An Inquiry Into Grifols SA For Potential Securities Violations And Stockholders Are Invited To Assist

NVDAMillionaire
NVDAMillionaire Oct. 3 at 2:31 PM
$GRFS Brilliant piece that captures GRFS's situation perfectly. So if you want to update your understanding of GRFS or get to know GRFS better, this is essential reading. https://beyondspx.com/quote/GRFS/analysis/grifols-nasdaq-grfs-plasma-powerhouse-unleashes-growth-and-deleveraging-momentum
0 · Reply
topstockalerts
topstockalerts Sep. 26 at 5:04 PM
U.S. plans for new pharmaceutical tariffs are seen as negative due to uncertainty but could be an “opportunity” for Grifols, which is fully vertically integrated in the U.S. Banco Sabadell analysts noted the 100% tariff announcement on foreign branded or patented drugs unless companies establish U.S. manufacturing. While the news creates noise, details remain unclear, especially for firms already present in the U.S. Sanofi has announced $ 20B investment in the U.S. through 2030. Grifols is expected to face no negative impact, with ~70% of plasma collection and ~65% of production capacity in the U.S. Analysts see tariffs as a potential advantage for Grifols, the only fully vertically integrated hemoderivatives company in the country. Almirall’s impact would be minimal (~4.5% of sales in the U.S.), and Rovi is unlikely to be affected due to no direct distribution or branded products in the U.S. $GRFS $SNY $ALM $ROVI
0 · Reply
TradeJizzer
TradeJizzer Aug. 14 at 2:18 AM
$GRFS Breaking on X: Grifols just got busted for taking donated blood and selling it. This may gap down in the am.
0 · Reply
Doozio
Doozio Aug. 2 at 6:15 PM
$GRFS dips appears a 🎁 during 🐒🍌🧠⏰♾️
0 · Reply
RunnerSignals
RunnerSignals Jul. 29 at 9:07 PM
$CELC $GRFS $HIMS $ECX $ODP Comeback Kings shook off the midday dips and closed strong
0 · Reply
DonCorleone77
DonCorleone77 Jul. 29 at 5:17 PM
$GRFS Grifols reports Q2 revenue EUR 1.89B vs. EUR 1.79B last quarter -- Q2 profit EUR 191M vs. EUR 115M last quarter. -- Reinstates dividend of EUR 0.15 per share -- Affirms 2025 guidance from capital markets day
0 · Reply
BeefStewart
BeefStewart Jul. 17 at 8:14 PM
$CERS Looks like some plasma-related stocks are just lagging $ADMA $GRFS ....
0 · Reply
Messerschmittbf109
Messerschmittbf109 Jun. 24 at 9:07 PM
$GRFS Grifols paid a higher price to buy blood plasma from an entity linked to its controlling family than from third-party suppliers, according to a regulator’s findings submitted in a court case ….
0 · Reply
Messerschmittbf109
Messerschmittbf109 Jun. 24 at 6:59 AM
$GRFS Grifols pagó hasta un 39% más para comprar plasma a Scranton Según las conclusiones de un regulador presentadas en un caso judicial, la farmacéutica española también acordó pagar a Scranton un margen fijo del 16,5% sobre los costes Bad news
0 · Reply
Messerschmittbf109
Messerschmittbf109 Jun. 23 at 8:15 PM
$GRFS bad news ? Weird day
0 · Reply
JarvisFlow
JarvisFlow Jun. 17 at 1:00 PM
JP Morgan updates rating for Grifols ( $GRFS ) to Neutral, target set at 7.6 → 10.3.
0 · Reply
DonCorleone77
DonCorleone77 May. 30 at 11:14 AM
$GRFS U.S. court rules to go on with Grifol lawsuit against Gotham City, Reuters says A New York court has found enough evidence to continue with the defamation lawsuit filed by Grifols against short seller Gotham City Research, Reuters reports. The Federal District Court for the Southern District of New York rejected Gotham City's request to dismiss the lawsuit, but did narrow it by rejecting some claims.
0 · Reply
ZacksResearch
ZacksResearch May. 28 at 2:57 PM
After a strong start, is $ADMA still the best bet, or is $GRFS taking the lead? 🏆 💡 ADMA boasts robust Asceniv demand and 15.9% gains in 2025, but trades at a pricey 25.48X forward earnings. 📈 Meanwhile, GRFS, with its wider portfolio and Zacks Rank #2 (Buy), offers a cheaper 7.19X valuation and a significant EPS improvement of 296% in 2025. Discover which stock could be your next winner 👉 https://www.zacks.com/commentary/2478303/adma-biologics-vs-grifols-which-plasma-therapy-stock-is-the-better-buy?cid=sm-stocktwits-2-2478303-body&ADID=SYND_STOCKTWITS_TWEET_2_2478303_BODY
0 · Reply
ZacksResearch
ZacksResearch May. 28 at 1:06 PM
At current levels, $GRFS scores over $ADMA with cheaper valuation, a broad portfolio, and strong EPS growth estimates despite the latter's robust Asceniv-driven momentum. Explore further: https://www.zacks.com/stock/news/2478303/adma-biologics-vs-grifols-which-plasma-therapy-stock-is-the-better-buy?cid=sm-stocktwits-2-2478303-teaser&ADID=SYND_STOCKTWITS_TWEET_2_2478303_TEASER
0 · Reply
RunnerSignals
RunnerSignals May. 22 at 9:39 PM
Fresh Upgrades and Downgrades After-Hours! $CR $INGN $GRFS $MU $SWK and more in play! Analysts reshuffled the deck - who's your pick going into Friday? stocksrunner.com/news/2025-05-22-thursday-analyst-upgrades-and-downgrades
0 · Reply
Messerschmittbf109
Messerschmittbf109 May. 10 at 6:04 AM
$GRFS bad candle last session
0 · Reply
Messerschmittbf109
Messerschmittbf109 Apr. 15 at 6:44 PM
$GRFS take over soon
0 · Reply
LewisWay
LewisWay Apr. 15 at 3:59 PM
$GRFS 🤫🤩 Holly s... check this out... I remember what they've did last time, it's a retail war against hedge funds... I'm in. BUY BUY BUY 🥳🤛🧨🚀🚀🚀
0 · Reply
Messerschmittbf109
Messerschmittbf109 Apr. 14 at 8:10 PM
$GRFS $JSPR take over .. this is the end of
0 · Reply
Messerschmittbf109
Messerschmittbf109 Apr. 14 at 7:31 PM
$GRFS over SMA.
0 · Reply
Messerschmittbf109
Messerschmittbf109 Apr. 14 at 5:56 PM
$GRFS $JSPR …
0 · Reply